IL1A and acute kidney injury: In contrast, a Cochrane-based meta-analysis of six randomized controlled studies of IL-1 inhibitors (anakinra or canakinumab) revealed no evidence for relevant benefits of the IL-1 inhibiting strategy in COVID-19 patients although AKI incidence and outcomes were not specifically assessed by the meta-analysis (92).